Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell entities : Immunitybio inc save search
ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer
Published: 2022-04-25 (Crawled : 13:20) - biospace.com/
IBRX | $4.91 -6.3% -6.5% 3M
|
Manufacturing
|
| O: -3.12%
H: 2.86%
C: 0.0%
trial cancer enroll
ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine Trial and Provides Update on Bladder Cancer BLA Filing
Published: 2021-12-20 (Crawled : 14:30) - biospace.com/
IBRX | $4.91 -6.3% -6.5% 3M
|
Manufacturing
|
| O: 1.53%
H: 1.2%
C: -2.41%
AMRS | $0.05 -21.88% -16.36% 47M
|
Process Industries
|
| O: -2.79%
H: 1.93%
C: -3.72%
als bladder cancer trials trial covid cel clinical trials cancer vaccine phase 3 merge t-cell bladder
ImmunityBio Announces Authorization to Proceed with Phase 1/2/3 Randomized Trial in South Africa of Their Dual-Antigen T-Cell Vaccine as a Universal Boost in Previously Vaccinated Participants Against COVID-19
Published: 2021-07-14 (Crawled : 13:15) - biospace.com/
IBRX | $4.91 -6.3% -6.5% 3M
|
Manufacturing
|
| O: 0.77%
H: 1.35%
C: -5.32%
covid phase 1 vaccine trial t-cell authorized africa
ImmunityBio Expands Trials of T-Cell-Based COVID-19 Vaccine Candidate as a ‘Universal Boost’ in Vaccinated Subjects and Receives Approval to Test Intranasal Spray in South Africa
Published: 2021-05-25 (Crawled : 13:15) - nantkwest.com
IBRX | $4.91 -6.3% -6.5% 3M
|
Manufacturing
|
| O: 2.23%
H: 2.37%
C: -1.93%
covid nasal spray test vaccine trial approval t-cell africa
ImmunityBio Announces NIH-Led Research Affirming that PD-L1 T-haNK Therapy Overcomes T-Cell Escape in Multiple Types of Resistant Tumors
Published: 2021-03-22 (Crawled : 14:00) - biospace.com/
IBRX | $4.91 -6.3% -6.5% 3M
|
Manufacturing
|
| O: -0.76%
H: 12.31%
C: 8.05%
therapy t-cell research
ImmunityBio Announces Positive Interim Phase I Safety Data of hAd5 T-Cell COVID-19 Vaccine Candidate in Oral and Sublingual Formulations
Published: 2021-03-15 (Crawled : 14:00) - biospace.com/
IBRX | $4.91 -6.3% -6.5% 3M
|
Manufacturing
|
| O: 2.0%
H: 3.34%
C: -1.06%
positive t-cell vaccine covid
Gainers vs Losers
| 60% | 40% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.